Diversification is a Good Thing

Jan 14, 2009

Daniel MacArthur follows up on Steven Pinker's NYT story about having his genome sequenced with a blog post on the diversification of consumer genomics. All four of the current consumer genomics companies have staked their claim, with 23andMe focusing on fun, deCodeMe on academics, Navigenics on medical accuracy, and Knome on boutique offering.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

UK Bioethics Group Gives Cautious OK for Genetically Modifying Human Embryos

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

CRISPR-Induced Damage?

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

'Fax' It Over

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

This Week in PNAS

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.

Main menu